Short answer: semaglutide and tirzepatide are both once-weekly injectable medications used in weight management and type 2 diabetes. Semaglutide activates one hormone receptor (GLP-1). Tirzepatide activates two (GIP and GLP-1). Which one, if either, is appropriate is a decision for a licensed clinician.
This article is educational and is not medical advice. Whether any treatment is appropriate for you is decided by a licensed clinician after reviewing your health history.
What is semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The FDA-approved semaglutide products are Wegovy (chronic weight management and cardiovascular-risk reduction in certain adults), Ozempic (type 2 diabetes), and Rybelsus (an oral tablet for type 2 diabetes). See MedlinePlus: semaglutide injection.
What is tirzepatide?
Tirzepatide is a dual agonist that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. The FDA-approved tirzepatide products are Zepbound (chronic weight management) and Mounjaro (type 2 diabetes). See MedlinePlus: tirzepatide injection.
How do they compare side by side?
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptors targeted | GLP-1 | GIP and GLP-1 |
| FDA-approved brands | Wegovy, Ozempic, Rybelsus | Zepbound, Mounjaro |
| How it's given (approved injectables) | Once-weekly injection | Once-weekly injection |
| Dosing approach | Starts low, increased gradually | Starts low, increased gradually |
| Main weight-management trial program | STEP | SURMOUNT |
| Common side effects | Nausea, vomiting, diarrhea, constipation, abdominal pain | Nausea, vomiting, diarrhea, constipation, abdominal pain, reduced appetite |
| Boxed warning | Thyroid C-cell tumors (rodent studies) | Thyroid C-cell tumors (rodent studies) |
What does the research cover?
Both medications have been studied in large randomized trials published in the New England Journal of Medicine:
- STEP 1 (2021) studied once-weekly semaglutide in adults with overweight or obesity. Wilding et al., NEJM
- SELECT (2023) studied semaglutide and cardiovascular outcomes in adults with obesity and without diabetes. Lincoff et al., NEJM
- SURMOUNT-1 (2022) studied once-weekly tirzepatide for the treatment of obesity. Jastreboff et al., NEJM
- SURMOUNT-5 (2025) compared tirzepatide with semaglutide directly in adults with obesity. Aronne et al., NEJM
These trials studied the FDA-approved medications. Compounded versions have not been separately studied or FDA-reviewed, and trial results do not carry over to them.
Which one is right for me?
Neither is presented here as better. The two differ in mechanism and side-effect profile, and the right choice — or whether either is appropriate — depends on your health history, other medications, and goals. At ElliotMeds, a licensed U.S. clinician reviews your full intake and makes that decision.
Who should not take either?
Both are not recommended for people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), for people with type 1 diabetes, or during pregnancy. See Who should not take a GLP-1 for the full list.
Learn more
Sources
- MedlinePlus — Semaglutide injection
- MedlinePlus — Tirzepatide injection
- DailyMed — Wegovy prescribing information
- DailyMed — Zepbound prescribing information
- Wilding et al., NEJM 2021 (STEP 1)
- Lincoff et al., NEJM 2023 (SELECT)
- Jastreboff et al., NEJM 2022 (SURMOUNT-1)
- Aronne et al., NEJM 2025 (SURMOUNT-5)
Every program includes a clinician chart review. When prescribed, treatments are filled by a licensed U.S. pharmacy.
Important note
Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing. A licensed clinician determines whether a treatment is appropriate based on the information provided.